Drug Profile


Alternative Names: BMS-562247; BMS-562247-01; Eliquis

Latest Information Update: 09 Dec 2016

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; Pfizer
  • Class 2 ring heterocyclic compounds; Amides; Anticoagulants; Antithrombotics; Lactams; Phenyl ethers; Pyrazoles; Pyridones; Small molecules
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Deep vein thrombosis; Pulmonary embolism; Stroke; Thromboembolism; Venous thromboembolism
  • Phase III Acute coronary syndromes

Most Recent Events

  • 18 Nov 2016 Bristol-Myers Squibb, Pfizer and Pediatric Heart Network plan a phase II trial for Thromboembolism (Prevention) in Argentina, Austria, Australia, Brazil, Canada, Finland, France, Germany, Israel, Italy, Mexico, Ireland, Netherlands, Spain, Sweden, United Kingdom and USA (NCT02981472)
  • 01 Oct 2016 Bristol-Myers Squibb completes a phase I pharmacokinetics trial in Healthy volunteers in USA (unspecified route) (NCT02912234)
  • 01 Sep 2016 Bristol-Myers Squibb initiates a phase I pharmacokinetics trial in Healthy volunteers in USA (unspecified route) (NCT02912234)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top